Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis (SEWORRA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by University Hospital, Rouen
Information provided by (Responsible Party):
University Hospital, Rouen Identifier:
First received: May 12, 2011
Last updated: June 18, 2014
Last verified: June 2014

To detect by sonography relapse of disease activity prior to clinical symptoms in RA patients treated by rituximab.

Condition Intervention Phase
Rheumatoid Arthritis
Device: ESAOTE MyLab60
Drug: Rituximab
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis

Resource links provided by NLM:

Further study details as provided by University Hospital, Rouen:

Primary Outcome Measures:
  • global score of power-doppler activity measured by ultrasonography on 12 joints [ Time Frame: at 6 months after initiation of rituximab and then every 2 month over the follow-up period (18 months) ] [ Designated as safety issue: No ]
    Each time point will be assessed since the main objective of the study is to detect the time of sonographic relapse prior to clinical relapse

Estimated Enrollment: 30
Study Start Date: February 2011
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rituximab
Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
Device: ESAOTE MyLab60
US evaluation at different time points
Other Name: sonography
Drug: Rituximab


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • failure to at least one TNF-blocking agent

Exclusion Criteria:

  • pregnant or childbearing woman
  • Rituximab contraindication
  • woman unable to use contraceptive means
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01765374

Contact: Olivier Vittecoq, MD,PHD +33 2 32 88 90 19

Department of Rheumatology, CHU de Caen Recruiting
Caen, France, 14033
Contact: Christian Marcelli, MD    33 2 31 06 31 06   
Normandy Enrolling by invitation
Caen, Le Havre, Rouen, Elbeuf, France
Department of Rheumatology Recruiting
Le Havre, France, 76290
Contact: Charles Zarnitsky    33 2 32 73 32 32   
Department of rheumatology Recruiting
Rouen, France, 76031
Contact: Olivier Vittecoq, MD,PhD    33 2 32 88 90 19   
Department of Rheumatology CHG Elbeuf Recruiting
Saint Aubin Les Elbeuf, France, 76410
Contact: Frenando da Silva, MD    33 2 32 96 35 35   
Sponsors and Collaborators
University Hospital, Rouen
  More Information

No publications provided

Responsible Party: University Hospital, Rouen Identifier: NCT01765374     History of Changes
Other Study ID Numbers: 2010/081/HP
Study First Received: May 12, 2011
Last Updated: June 18, 2014
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Rouen:
clinical response

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 24, 2014